Jr. Grandis et al., LEVELS OF TGF-ALPHA AND EGFR PROTEIN IN HEAD AND NECK SQUAMOUS-CELL CARCINOMA AND PATIENT SURVIVAL, Journal of the National Cancer Institute, 90(11), 1998, pp. 824-832
Background: The most accurate predictor of disease recurrence in patie
nts treated for head and neck squamous cell carcinoma is, at present,
the extent of regional lymph node metastasis, Since elevated levels of
epidermal growth factor receptor (EGFR) and of its ligand, transformi
ng growth factor-alpha. (TGF-alpha), have been detected in primary tum
ors of patients with head and neck squamous cell carcinoma, we determi
ned whether tumor levels of these proteins were of prognostic importan
ce. Methods: Monoclonal antibodies specific for EGFR and TGF-alpha wer
e used for immunohistochemical detection of each protein in tissue sec
tions of primary tumors from 91 patients who were treated by surgical
resection, Levels of immunoreactive EGFR and TGF-alpha were quantified
by use of a computerized image analysis system and were normalized to
appropriate standards. The logrank test and proportional hazards regr
ession analysis were used to calculate the probability that EGFR and T
GF-alpha levels were associated with disease-free survival(i.e., no re
currence of cancer) and cause-specific survival (i.e., patients do not
die of their disease). All P values were two-sided. Results: When tum
or levels of EGFR or TGF-alpha were analyzed as continuous variables,
disease-free survival and cause-specific survival were reduced among p
atients with higher levels of EGFR (both P = .0001) or TGF-alpha (both
P = .0001), In a multivariate analysis, tumor site, tumor level of EG
FR, and tumor level of TGF-ar were statistically significant predictor
s of disease-free survival; in a similar analysis, regional lymph node
stage and tumor levels of EGFR and of TGF-alpha were significant pred
ictors of cause-specific survival. Conclusion: Quantitation of EGFR an
d TGF-alpha protein levels in primary head and neck squamous cell carc
inomas may be useful in identifying subgroups of patients at high risk
of tumor recurrence and in guiding therapy.